Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agalsidase beta (Fabrazyme) in Chinese Fabry disease patients
CTR20212177Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Started Sep 2021; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on CTR20212177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212177.